Broad Institute

JANUARY 30, 2024

Bhattacharyya wears many coats today, splitting his time between the Broad and the infectious disease ward at MGH, where a diagnostic method he developed at Broad is now being tested to see if it helps patients quickly receive the best antibiotics for their infections. A combined MD/PhD program offered both opportunities.

Hospitals 137

Hospitals Medical Schools Virus Science 137

Drug Target Review

JUNE 11, 2024

When choosing my bachelor’s degree, the choice was between pursuing a career in biology or in computer science. Biology won that battle, and I pursued a bachelor’s and master’s degree in biochemistry and molecular biology.

Engineering 63

Engineering Science Molecular Biology Doctors 63

Elrig

APRIL 29, 2024

She is currently a Senior drug discovery scientist working across Cell Engineering, Cell Biology and Functional Genomics teams, using CRISPR/Cas9 and Next Generation Sequencing for target identification, target validation and drug development in the oncology disease area.

Bioinformatics 59

Bioinformatics Molecular Biology Drugs Cell Based Assays 59

Drug Discovery World

NOVEMBER 9, 2023

Alessa Schaffrath, Doctoral Student, UKE Hamburg, on: ‘Transgenic llama mice – a fast and flexible single domain discovery tool’. Phil Leighton, PhD, Senior Director, Molecular Biology, OmniAb, on: ‘Heavy chain-only transgenic chickens produce human antibodies with robust immune repertoires and high-affinity binding’.

Engineering 130

Engineering Protein Production Therapies Science 130

Drug Target Review

AUGUST 29, 2023

I then chose to do my doctoral research at the Perelman School of Medicine at the University of Pennsylvania, which provided me with great scientific training, critical thinking, and communication skills. in cell and molecular biology with a focus in cancer biology from the Perelman School of Medicine at the University of Pennsylvania.

Science 98

Science Molecular Biology Disease Therapies 98

Drug Discovery World

AUGUST 16, 2022

Numerous underlying factors, ranging from genetics, environment, lifestyle, co-morbidities, income level, ethnicity, and beyond, converge to influence an individual’s risk for cancer and how the disease is managed. Instead, molecular markers are more accurate indicators of the patient’s associated risks. .

Research 130

Research Clinical Trials Trials Drug Development 130

Codon

FEBRUARY 13, 2024

alone, according to the Centers for Disease Control and Prevention. ” A Global View Even as advances in computing and molecular biology usher in the era of a new, high-tech “phage therapy 2.0”, At least a million people die from drug-resistant bacterial infections every year.

Therapies 138

Therapies DNA Virus Clinical Trials 138

Codon

JULY 27, 2023

CNGA3-achromatopsia is a hereditary disease that causes people to see in shades of gray. in Current Biology. There’s a TV show where a bunch of doctors are walking through a hospital corridor. They’re talking about a patient who has a rare genetic disease. ” Gene-edited poplar tree stems appear red.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

CNGA3-achromatopsia is a hereditary disease that causes people to see in shades of gray. in Current Biology. There’s a TV show where a bunch of doctors are walking through a hospital corridor. They’re talking about a patient who has a rare genetic disease. ” Gene-edited poplar tree stems appear red.

Therapies 52

Therapies RNA DNA Engineering 52

Drug Discovery World

NOVEMBER 10, 2023

I was fortunate to join the four-year Wellcome Trust PhD programme, which allowed me to dabble in three areas of biology (genetics/ molecular biology, virology and parasitology) before embarking on my PhD, which combined elements of all of these placements. MT: What drives you professionally and personally?

Molecular Biology 147

Molecular Biology Clinical Trials Licensing Licensing 147